Report: Früherkennungsmonitor 2023 (Germany): Difference between revisions
m (Update categories.) |
m (Update categories.) |
||
| Line 61: | Line 61: | ||
<span style="display:none">hasCancerType::C60-C63: Male genitalia cancer</span> | <span style="display:none">hasCancerType::C60-C63: Male genitalia cancer</span> | ||
<span style="display:none">isReport</span> | <span style="display:none">isReport</span> | ||
<span style="display:none">hasCancerType::C00-D48: All neoplasms</span> | |||
<span style="display:none">hasCancerType::C00-C97: All cancer types</span> | |||
Revision as of 11:28, 6 December 2025
Go back to Germany page
Primary purpose: To analyze and provide an overview of the utilization of cancer early detection services offered by the German statutory health insurance (GKV).
Sponsor, manager or home institution: Wissenschaftliches Institut der AOK (WIdO).
Type of information: The report outlines cancer screening services covered by the German statutory health insurance (GKV), including screenings for cervical, prostate, colorectal, breast, and skin cancers, as well as general health checks and screening for abdominal aortic aneurysms. It tracks usage rates of these screenings from 2019 to 2022, noting the impact of the COVID-19 pandemic on participation. A key focus is colorectal cancer screening, analyzing trends in colonoscopy usage for diagnostic and preventive purposes. The report also discusses changes in cancer mortality and cancer incidence in Germany, highlighting declines in certain cancers due to early detection. Additionally, it addresses challenges like false positives and examines regional differences in screening uptake. Click here to learn more.
Data level: national level.
Cancer areas of interest: C15-C26: Digestive system cancers, C43-C44: Skin cancers/melanoma, C50: Breast cancer, C51-C58: Female genitalia cancer, C60-C63: Male genitalia cancer. Click here to learn more.
Access to information: Click here to access.
